To determine the safety and efficacy of a change in blood glucose (BG) control protocol from a single target to 2 targets based on diabetes status and glycated hemoglobin (A1C) in a cohort of critically ill patients.
Introduction
Our understanding of the relationship of glycemia to outcomes of critically ill patients has evolved considerably in the 15 years since publication of the first randomized trial of intensive insulin therapy.
1 Observational 2-10 and randomized trial data 11, 12 have demonstrated that hyperglycemia, hypoglycemia and increased glucose variability are independently associated with mortality. In addition, an emerging body of literature has highlighted differences in the relationship of glucose metrics to outcomes when comparing patients with and without diabetes [13] [14] [15] [16] and a review of the interventional trials of intensive insulin therapy suggested greater benefit of treatment among patients without diabetes. 17 Observational data has underscored the importance of preadmission glycemia. Among a cohort of critically ill diabetic patients, those with A1C levels > 7% had higher probability of death with lower mean BG levels during ICU stay and higher probability of survival with higher mean BG levels during ICU stay while patients with A1C levels < 7% fared better with lower BG levels during ICU stay. 18 Similarly, another observational study reported that early hyperglycemia was associated with death only in patients with A1C < 6.5%. 19 Finally, in a multi-center cohort the relationship between hypoglycemia and mortality was strongest among those with the highest A1C comparing those with and without DM. 20 While the major interventional trials of intensive insulin therapy targeted "euglycemia," 80-110 mg/dL, these data suggest that a single glycemic target may not be suitable for all patients admitted to the ICU. Two small before and after observational studies, including a total of 80 and 82 patients, respectively, have recently reported results of implementing 2 BG targets in cohorts of patients with diabetes. 21, 22 DOI:10.4158/EP161532.OR © 2016 AACE.
This current investigation evaluates the safety and feasibility of implementation of 2 BG targets in a much larger cohort of patients admitted to a single mixed medical-surgical ICU. In the first year all patients were treated with the same BG target; in the second year patients were treated to a personalized BG target based on preadmission glycemia. We hypothesized that this strategy would be safe and would be associated with reductions in mortality.
Patients and methods

Patients and Setting
This is a retrospective review of prospectively collected data involving 1,979 patients admitted consecutively to the Stamford Hospital Intensive Care Unit (ICU) between September 16, 2013 and September 15, 2015, comparing glucose metrics and mortality before and after a change in blood glucose (BG) management. Stamford Hospital is a 305-bed university affiliated teaching hospital; the 16 bed ICU treats a wide variety of medical, surgical, and trauma patients. Orders in the ICU are written by medical and surgical house staff supervised by a team of medical and surgical intensivists. The nurse:patient ratio is 1:2 or 1:1 depending on patient acuity. This analysis excluded patients admitted to the ICU following cardiovascular surgery since all patients continued to be treated with the more intensive glucose management protocol during the interventional era, irrespective of the diabetes status. In addition, we excluded patients admitted to the ICU with a diagnosis of diabetic ketoacidosis or hyperosmolar coma (see Figure 1 ). ("TIGHT" protocol). The BG target was 110-160 mg/dL in the POST era for DM with A1C > 7%
("LOOSE" protocol). Diabetes status was assigned at the time of admission for all patients based on all available information, including medical history and electronic databases of outpatient medication administration. Nurses treat hyperglycemia using guidelines embedded into the electronic medical record (PRE and POST guidelines found in Supplemental files 1a-c) and record data and insulin treatment in the electronic medical record. The insulin treatment protocols used in the ICU are nurse-driven, allowing a degree of discretion about insulin dosing.
Blood glucose monitoring is performed at a minimum of every 3 hours; if a patient requires continuous insulin infusion the monitoring frequency is increased to hourly. [13] [14] [15] [16] [17] [18] In particular, a large multi-center investigation demonstrated that mean glycemia 80-140 mg/dL was independently associated with decreased risk of mortality among patients without DM but was independently associated with increased mortality among patients with DM. 13 We based our decision to choose different BG targets for patients with DM based on A1C values on an observational study conducted in critically ill diabetic patients. 18 Finally, we chose the target of 110-160 mg/dL for the "LOOSE" DM cohort for practical reasons; by choosing an upper limit of 160 mg/dL we hoped to minimize BG excursions above 180 mg/dL, a level of glycemia associated with increased risk of morbidity and mortality in multiple studies of patients with and without DM.
Statistical methods
We compared clinical characteristics and glucose metrics of patients in the entire PRE and POST cohorts and we also analyzed these data stratified by diabetes status. We calculated Acute
Physiology and Chronic Health Evaluation (APACHE) II and IV scores as well as APACHE IV predicted mortality (%) prospectively as part of routine care. 24 POST era. We calculated observed:expected mortality ratios, using APACHE IV predicted mortality and compared them using the Z-test for independent proportions for between group comparisons. 26 
We report continuous data as median (interquartile range [IQR]) or mean (standard deviation
[SD]) and compare groups using Mann-Whitney rank sum test or Student's t-test, as appropriate.
We report categorical data as percentages and compare groups using the Chi-square test. We assigned the threshold for statistical significance as p<0.05.
We used the MedCalc statistical package (Brussels, Belgium) version 14. Clinical characteristics Table 1a details clinical characteristics of the 2 cohorts. There was a similar distribution of diagnostic categories, percentage of patients with diabetes, age and severity of illness scores.
ICU length of stay (LOS) was 7 hours longer in the POST era, likely in part due to the slightly higher percentage of patients with medical service admissions during this period. Supplementary Table 1 details results of multivariable analysis for mortality, demonstrating that ICU LOS was not independently associated with mortality in either era. Insulin treatment and glucose metrics Table 2 includes details about glucose metrics and insulin treatment of the cohorts. Among NON, the POST era was associated with a lower A1C, a slightly lower mean BG, lower maximum BG and lower minimum BG. Among DM, glucose metrics were similar when comparing PRE and the entire POST group. However, during the POST era patients treated with the LOOSE target had higher mean BG levels, higher maximum BG levels, higher glucose variability, and tended to have less hypoglycemia than those treated with the TIGHT protocol. Among DM, more than 4/5 received insulin in both periods, while approximately ½ of NON received insulin.
A total of 692 patients had at least one BG > 180 mg/dL. 
Conclusions
This before and after interventional investigation evaluated the impact of a change in hyperglycemia management protocol from a single BG target to 2 targets, based on preadmission glycemia and diabetes status, on glucose metrics and mortality in a large cohort of heterogeneous adult patients admitted to a single university affiliated teaching hospital. The intervention was found to be safe, with low rates of moderate hypoglycemia (< 70 mg/dL) and very low rates of severe hypoglycemia (< 40 mg/dL) in both eras. Among those with diabetes in the POST era, those treated with the "TIGHT" protocol had significantly lower mean ICU glycemia, reflected by mean BG as well as time in BG range, than did those treated with the "LOOSE" protocol. Comparing the 2 eras, mortality of NON patients was nearly identical, as was the observed:expected mortality ratio, using APACHE IV methodology. In contrast, among patients with diabetes there was a nonsignificant 17.3% reduction in mortality during the 2nd era, as well as a significant reduction in the observed:expected mortality ratio from 0.69 to 0.52 (p<0.001); for diabetes patients with A1C > 7% the corresponding values were 29.8% and 0.74 to 0.52 (p=0.004).
An evolving literature describing differences in outcomes of critically ill patients associated with preadmission glycemic control provided the rationale for the design of this investigation. In addition, a recently published multi-center observational study suggested that preadmission glycemia modulates the relationship between hypoglycemia and death in critically ill patients. 20 First, patients with higher pre-admission A1C levels were at significantly greater risk of hypoglycemia while in ICU than were those with lower levels of preadmission glycemia. Notably, there was a direct correlation between the degree of chronic hyperglycemia before ICU admission and mortality rate among patients who experienced hypoglycemia during ICU treatment.
The strengths of this investigation include the comprehensive nature of the dataset, especially detailed glucose metrics and outcome analysis, including severity adjusted mortality, as well as the large size of the cohort. We acknowledge several important limitations. First, this is a single center study, therefore potentially limiting its external validity, and the number of patients with diabetes was relatively small. Second, we cannot report data regarding nutritional support or insulin therapy, important factors that certainly modulate the relationship between ICU glycemia and outcomes. Third, BG values were obtained using point of care glucose meters, as is the standard of care in most ICU's in the United States. This technology is associated with greater analytic inaccuracy than are BG values obtained using arterial blood gas analyzers 33 , as well as the likelihood of "missed" episodes of hypoglycemia and hyperglycemia due to the intermittent nature of monitoring. 34, 35 Fourth, for those with diabetes we do not have data on pre-admission medications. We speculate that some of the newer diabetes therapies, either directly, or indirectly, (specifically the incretins and SGLT2 inhibitors) could impact outcomes due to each agent's different impact on inflammatory activation and hormonal changes (including brain naturetic peptide). 36 Fifth, the investigation uses A1C measurements to stratify patients and their treatment. This measurement can be variable dependent on ethnicity and can be unreliable in patients with hematologic conditions such as hemolytic anemia or hemoglobinopathies, as well as in those with mechanical heart valves, hypothyroidism or taking certain medications. 37 Moreover, and perhaps most importantly, differential glycation rates may lead to variability in A1C levels. Finally, this is a before and after, rather than randomized, investigation. Therefore, any conclusions must be considered hypothesis generating, and not as proof of causality.
Important questions remain. Consistent with other studies 10,13-16 these data support a BG target of 80-140 mg/dL for patients without diabetes, and perhaps, as well, for patients with diabetes who have excellent preadmission glycemic control, reflected by a low A1C or potentially other biomarkers if there is a "glycation gap". 37 Nevertheless, the appropriate BG target for diabetic patients, especially of those with A1C levels > 7%, is less clear. Available data suggest the need for a higher BG target in these patients than that used to treat those without diabetes. [13] [14] [15] [16] However, should this target range be 110-160 mg/dL, 140-180 mg/dL, or even higher? The "moderately loose" target of 110-160 mg/dL for those with A1C levels > 7% in this study was chosen with the intent of avoiding glucose excursions above 180 mg/dL, the usual threshold for glucosuria 38 and a level of hyperglycemia associated with increased risk of death in observational data in unselected individuals with diabetes 4,13 as well as increased risk of nosocomial infection. 
Important Points:
-Protocol is initiated by RN, when there is one BG > 300, or two consecutive BG > 180. MD must be notified regarding initiation of insulin drip. IV regular insulin is administered at concentration of 1unit/mL.
-All patients receiving continuous insulin with a BG <200 must receive a continuous source of glucose, either via D5W, D10W, TPN or enteral feeds.
-BG monitoring frequency is Q1 hr.
-Patients with severe shock or severe edema should have BG monitored using venous or arterial blood, rather than fingerstick capillary blood.
-If BG has not decreased after 2 BG, insulin dose should be increased.
-If BG control stabilizes (4 consecutive BG between 90-120 mg/dl) on the infusion, monitoring frequency can be decreased to Q2hours.
-Variances to the protocol are documented by the RN in Meditech and the MD is notified.
RISK OF HYPOGLYCEMIA INCREASES:
-In patients not receiving nutrition. Consider holding insulin in this case.
-In patients with ESRD or liver failure. Treat initially with 50% suggested insulin dose and consider increasing the frequency of BG monitoring.
ICU Subcutaneous Insulin Protocol
Goal: To bring blood glucose (BG) to a level between 90-120 mg/dl Important Points:
-Protocol is initiated upon patient s admission to ICU, or transition from IV insulin drip. Aspart insulin is the designated sc insulin.
-BG monitoring frequency is Q3 hr unless the patient is on po diet, in which case BG is monitored AC/HS.
-If the daily Aspart dose exceeds 15 units, addition of Glargine insulin should be considered. Glargine should be administered Q12 hrs. The starting Glargine dose should be 33% -Aspart dose.
-Oral hypoglycemic agents should not be used in the ICU. 
ICU Insulin Drip Protocol
Goal: To bring blood glucose (BG) to a level between 90-120 mg/dl When BG rate of change >50 mg/dL:
-If BG is between 200-300 with greater than 100 BG drop since the previous BG, decrease drip rate by 50% recheck in 1 hour.
-If BG is between 150-200 with greater than 50 BG drop since the previous BG, decrease drip rate by 50% recheck in 1 hour.
When BG rate of change >50mg/dL:
-If BG is between 200-300 with greater than 100 BG drop since the previous BG, decrease insulin dose by 50% and recheck BG in 1 hour.
-If BG is between 150-200 with greater than 50 BG drop since the previous BG decrease insulin dose by 50% and recheck BG in 1 hour.
This protocol is not to be used for patients being treated for diabetic ketoacidosis. These guidelines can be modified if the patient requires more or less intensive therapy. 
NON DIABETICS, DIABETICS w/ A1C <7, CV SURGERY ICU GLYCEMIC CONTROL PROTOCOL
70-89
Stop insulin infusion. Check BG Q1H x 2 hours.
40-69
Stop insulin infusion: initiate D10 @ 100mL/hr. Check BG in 30 min and 60 min. Stop D10 infusion when BG >79.
<40
Stop insulin infusion. Give1/2 amp D50. Check BG in 30 min. Notify MD.
Important points:
-Protocol is initiated by RN when there is one BG > 300 mg/dL, or two consecutive BG > 180 mg/dL. Notify MD. -CV SURGERY insulin drip initiated during surgery will be maintained until 24 hours after ICU admission -All patients receiving continuous insulin with a BG <220 must receive a continuous source of glucose, either via D5W, D10W, TPN or enteral feeds. -BG monitoring frequency is Q1H. 
70-79
If asymptomatic, check BG in 1 hour. If symptomatic, treat using 40-69 mg/dL guidelines.
40-69
If ordered for PO intake, give 120mL of apple juice. If NPO initiate D10 @ 100mL/hr and check BG in 30 min and 60 min. Stop D10 infusion when BG >89 mg/dL.
<40
Give 1/2 amp D50. Check BG in 30 min. Notify MD.
Important points:
-IV insulin drip. -Novolog insulin is the designated SC insulin. -BG monitoring frequency is Q3H unless the patient is on PO diet, in which case BG is monitored AC/HS. -0-140 mg/dL range without insulin requirement for 48 hours, BG monitoring frequency can be decreased to Q6H.
